Skip to main content
NewslettersWatchlist

Arbutus Biopharma Cp(ABUS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low2.69
Day High2.80
Open:2.78
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
GlobeNewswire
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
GlobeNewswire
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
GlobeNewswire
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
GlobeNewswire
Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®
GlobeNewswire
Arbutus to Present at Jefferies London Healthcare Conference
GlobeNewswire
Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
Arbutus Announces CEO, William Collier, to Retire December 31, 2023
GlobeNewswire
Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update
GlobeNewswire
Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference
GlobeNewswire
Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023
GlobeNewswire
Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
GlobeNewswire
Arbutus to Participate in Two Upcoming Investor Conferences
MarketBeat
3 Stocks to Buy For the COVID Resurgence
GlobeNewswire
Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
GlobeNewswire
Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update
GlobeNewswire
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
GlobeNewswire
Arbutus Appoints Two New Executives
GlobeNewswire
Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody
GlobeNewswire
Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
GlobeNewswire
Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS
PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS
Motley Fool
Why Arbutus Biopharma Stock Is Sinking Today
SYNDTGAM
Arbutus files patent infringement lawsuit against Pfizer and BioNTech over COVID-19 vaccines
Motley Fool
Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript
Globe Newswire
Arbutus Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
Globe Newswire
Arbutus Biopharma Provides Update on the Phase 2A Combination Trial with AB-729 and a Capsid Inhibitor

Profile

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.